Summary
Introduction
[ 18 F]dopa-PET provides an in vivo method for assessing the functional integrity of pre-synaptic dopaminergic function in reconstruction and analysis of dynamic [ 18 F]dopa-PET data (Rakshi et al., 1996) , resulting in a fourfold increase in the sensitivity of brain signal to noise ratios in 3D compared with 2D acquired PET studies (Cherry et al., 1991; Bailey, 1992) . In addition, the increased sensitivity enables a higher reconstructed resolution with a reduction in the partial volume effects leading to a further overall improvement in image quality. Therefore, 3D [ 18 F]dopa-PET should be more sensitive and accurate at detecting focal changes within extrastriatal and striatal dopaminergic regions (see Fig. 1 ).
The conventional method of [ 18 F]dopa analysis uses a region of interest approach with multiple time graphical analysis (MTGA) (Patlak and Blasberg, 1985) to sample putamen and caudate function. However, the size, shape and placement of these regions is arbitrary, producing interand intra-observer variation, and potential observer bias. Furthermore, in severe Parkinson's disease it can be difficult to identify the striatal boundaries for placement because of the reduced [ 18 F]dopa uptake.
We have applied statistical parametric mapping (SPM) to 3D [ 18 F]dopa-PET studies, enabling us to objectively localize focal changes in dopaminergic function in Parkinson's disease throughout the brain volume without having to make an a priori hypothesis as to their location. SPM was initially developed for PET activation studies and localizes significant differences in function in spatially normalized brain images on a voxel-by-voxel basis (Friston et al., 1991b) . SPM has now been applied to a number of PET ligands including [ 11 C]flumazenil to localize changes in GABA A receptor binding in focal epilepsy (Richardson et al., 1996) and to [ 11 C]diprenorphine to study alterations in opioid receptor binding in Huntington's and Parkinson's disease (Weeks et al., 1995; Piccini et al., 1997) .
In addition to applying SPM, we employed the standard region of interest and MTGA analytical approach (Brooks et al., 1990b) to sample striatal and midbrain regions in untransformed images and, subsequently, brain areas revealed by SPM to have altered dopaminergic function in Parkinson's disease.
Subjects and method Subjects
Seven patients with early hemi-Parkinson's disease clinically affecting their left limbs [mean age 57 Ϯ 5 years; mean motor Unified Parkinson's Disease Rating Scale (UPDRS) score 9 Ϯ 3 (range 4-12); Hoehn and Yahr stage 1; and mean symptom duration 19 Ϯ 5 months] and seven patients with advanced bilateral Parkinson's disease [five left dominant, two right dominant; mean age 54 Ϯ 8 years; mean motor UPDRS score 41 Ϯ 15 (range 22-66); Hoehn and Yahr stage 3-5; and mean symptom duration 12 Ϯ 4 years] underwent [ 18 F]dopa-PET scanning. Findings were compared with those of a group of 12 normal subjects, mean age 57 Ϯ 11 years.
All patients fulfilled the UK Parkinson's disease Brain Bank criteria for idiopathic Parkinson's disease (Gibb and Lees, 1988) . All Parkinson's disease patients were on regular levodopa therapy except for two of the early Parkinson's disease patients who were drug naive. In addition, three of the advanced Parkinson's disease patients were taking a dopamine agonist, and two a monoamine oxidase-B inhibitor.
Each patient had their medication stopped at least 12 h before their PET scan and was clinically assessed by a single observer, using the UPDRS and Hoehn and Yahr rating scales (Hoehn and Yahr, 1967; Fahn and Elton, 1987) just before their scan. Parkinson's disease patients with significant cognitive impairment, as assessed by the Folstein's MiniMental Test (Folstein et al., 1975) , were excluded from the study (Ͻ28 out of 30). All controls had a normal neurological examination and showed no evidence of rest tremor, rigidity or bradykinesia. No normal volunteer was taking medication.
All patients and normal volunteers gave written informed consent, after a full explanation of the procedure. Permission to perform these studies was granted by the Ethics Committee of the Royal Postgraduate Medical School, London, UK and the Administration of Radioactive Substances Advisory Committee (ARSAC), UK.
Scanning protocol
In addition to having their medication stopped 12 h before their PET scan, all subjects were fasted on the morning of the scan and received an oral bolus of 150 mg carbidopa and 400 mg entacapone, a peripheral catechol-O-methyl transferase inhibitor (COMT; Orion Farmos Pharmaceuticals Espoo, Finland) 1 h before scanning (Sawle et al., 1994; Ishikawa et al., 1996a) .
The [ 18 F]dopa-PET scans were performed with an ECAT 953B neuroscanner (CTI/Siemens, Knoxville, Tenn., USA), with an axial field of view of 10.8 cm, and in 3D acquisition mode with protocols that have been previously reported (Bailey, 1992) , yielding 31 planes with a slice separation of 3.4 mm and an average in-plane resolution of 6 mm fullwidth half-maximum. A correction for tissue attenuation of 511 KeV gamma radiation was measured with a 10 min 2D transmission scan performed prior to tracer injection and acquired using retractable 68 Ga/ 68 Ge sources.
[ 18 F]Dopa (140-180 Mbq in 10 ml of normal saline solution) was infused intravenously over 30 s. Scanning began at the start of the tracer injection with a protocol of 25 time frames over 94 min (4 ϫ 1 min, 3 ϫ 2 min, 3 ϫ 3 min, 15 ϫ 5 min). The subjects were positioned such that the orbitomeatal line was parallel to the transaxial plane of the tomograph and head position was carefully monitored throughout the scan.
Data analysis
Two methods of analysis were employed: (i) SPM and (ii) standard region of interest approach with MTGA. Analysis of data was performed on a SUN Sparc 10 workstation (Sun Microsystems, Silicon Valley, Calif., USA) using ANALYZE 7.0 (Mayo Foundation, Baltimore, Md., USA) (Robb and Hanson, 1991) (Friston et al., 1991a) . We have, therefore, developed an indirect approach whereby we use the combined time frames 1-25 of the dynamic 3D [ 18 F]dopa image to produce an integrated 'add image' (0-94 min). This 'add image' contains the earlier time frames which are blood flow dependent and so generates sufficient cortical as well as striatal detail to allow accurate spatial normalization to the SPM template (see Fig. 2 ). Applying this method we produced an 'add image' for each subject and spatially normalized it to the rCBF template. The resulting transformation parameters were then applied to the corresponding subject's parametric image of [ 18 F]dopa K i o , allowing all the parametric images to be transformed into the standard stereotaxic space of Talairach and Tournoux (Rakshi et al., 1998) .
This then allowed comparisons to be made across scan (b) and (c) were localized using SPM. The contrasts were used to derive between-group Z scores (unpaired t statistic transformed to the standard normal distribution) on a voxel-by-voxel basis using the general linear model (Friston et al., 1991b (Friston et al., , 1995 . The P values associated with these regional effects were corrected for multiple-dependent comparisons implicit in the SPM. Maps of Z scores surviving a threshold of Ͼ2.33 (P Ͻ 0.01) were further corrected for multiple comparisons. These surviving voxels were rendered on to a stereotactically normalized MRI (see Fig. 3 ).
Region of interest analysis
We applied standard region of interest and MTGA analysis to the original untransformed datasets to sample frontal, midbrain and striatal regions. The influx rate constants [ 18 F]dopa K i o s were calculated from the time frames 14-25 (30-94 min) post-injection for tissue count activity using occipital tissue counts as the input function. For the striatum, circular regions of 10 mm diameter were placed over each dorsal head of caudate and an elliptical region of 10 ϫ 24 mm over each dorsal putamen aligned to the long axis on three contiguous transverse planes.
With the increased resolution and sensitivity of our 3D [ 18 F]dopa-PET scanner, we were now able to identify the midbrain and frontal regions more clearly by visual image inspection and with reference to the stereotaxic atlas (Talairach and Tournoux, 1988) . We sampled the midbrain region by placing a single circular region of 16 mm diameter, encompassing both ventral and dorsal midbrain regions, on two contiguous transverse planes. We retrospectively sampled the anterior cingulate region. This was achieved by initially identifying the region of interest on the stereotaxic atlas using the coordinates of the frontal focus determined from the SPM analysis. We then identified this region on the [ 18 F]dopa-PET scan by the position of the anterior cingulate cortex in relation to the striatum on the PET image. However, because this method is imprecise, we used regions encompassing a larger volume than the SPM focus so that the region of interest would be included. Two circular regions of interest of diameter 16 mm for right and left anterior cingulate regions corresponding to the foci where significant increases in [ 18 F]dopa K i o values were observed with SPM analysis were applied.
For the input function, we sampled right and left occipital lobes with two circular regions of 32 mm diameter placed on the same three contiguous planes as those selected for the dorsal striatal regions. All regions of interest were placed manually using the IDL software.
The 
Results

Frontal region SPM analysis
In early left hemi-Parkinson's disease we observed a significant increase in [ 18 F]dopa K i o in the the left anterior cingulate gyrus (Brodmann area 24/32) compared with the normal control group (Table 1 and Fig. 3A ). There was also a similiar trend in the right cingulate but this did not reach statistical significance on correction (Z ϭ 3.8, P Ͻ 0.076).
In advanced Parkinson's disease, no significant change in mean cingulate [ 18 F]dopa K i o was observed, either when compared with the normal controls or directly with the early hemi-Parkinson's disease group. Fig. 3B ).
Region of interest analysis
In the direct comparison of advanced bilateral Parkinson's disease with early hemi-Parkinson's disease significant reductions in mean [ 18 F]dopa K i o were observed in the dorsal pons as well as the dorsal and ventral midbrain regions and striata (Table 1 and Fig. 3C ).
No significant changes in midbrain [ 18 F]dopa K i o were found in early hemi-Parkinson's disease (Table 2 ).
In the advanced Parkinson's disease group there was a 28% reduction in mean midbrain [ 18 F]dopa K i o at the level of the nigra compared with normal controls.
Striatal regions SPM analysis
A comparison of the early left hemi-Parkinson's disease with the normal control group showed significant reductions in mean [ 18 F]dopa K i o throughout the right and left putamen; these were more widespread and significant in the right putamen (Table 1 and Fig. 3D ). In addition to the main putamen focus, there was also a second focus located in the right anterior putamen which extended into right head of caudate and a further separate focus in the dorsal body of the right caudate (Table 1 and Fig. 3D) .
In advanced Parkinson's disease compared with the normal control group, more extensive and highly significant reductions in [ 18 F]dopa K i o values were found throughout both the dorsal and ventral striata (Table 1 and Fig. 3E ).
In the direct comparison of advanced bilateral Parkinson's disease (left-dominant) with early left hemi-Parkinson's disease, interestingly, only the relative further reduction in left putamen reached statistical significance at P Ͻ 0.05, corrected (Table 1 ). There was a trend, however, towards relative reductions throughout the striata (P Ͻ 0.05, uncorrected).
Region of interest analysis
In the early left hemi-Parkinson's disease group there was a 64% and 44% reduction in mean right and left putamen [18] (Table 2 ). There were 
Methodological issues
In practice, as with all methods and measurements, there are sources of error in the technique, and their understanding is required for the proper interpretation of the results. The main methodological issues are: 3D PET data acquisition, quantification and interpretation of [ 18 F]dopa uptake, and the application of SPM to [ 18 F]dopa datasets.
3D scanning has a great sensitivity advantage over 2D acquisition. The technique, however, is complex and some of the problems involved have yet to be completely resolved (Badawi, 1997) . In 3D mode or volume imaging, the interplane septa of the PET scanner are removed and coincidence events may be detected by pairs of detectors located in any ring. This greatly increases the camera sensitivity to true coincident events, but also increases the sensitivity to scattered coincidences. One therefore has to employ a scatter correction method for 3D datasets (Cherry et al., 1993; Bailey and Meikle, 1994) . Another difficulty relates to the requirement that all pairs of detectors in coincidence should have the same sensitivity, i.e. detector normalization. It has been shown that there is no unique normalization for both scatter and true coincidences or for all counts rates. Detector normalization is not perfect and is still being improved. Finally, because of the high count rates that detectors have to process in 3D acquisition, there is an increase in dead-time and random coincidence events detected. Ingenious methods to overcome these limiting factors in 3D mode are currently being developed.
Nevertheless, accepting the problems and limitations above, we have implemented 3D [ 18 F]dopa-PET and successfully performed a validation experiment. We have also demonstrated improved image quality and reproducibility compared with our previous 2D protocol (Rakshi et al., 1996; Trebossen et al., 1996) PET is to measure a biological variable of interest to the pathophysiology of Parkinson's disease. With [ 18 F]dopa-PET, we would ideally like to measure k 3 , the rate constant which directly reflects aromatic amino acid decarboxylase activity (AADC) and thus pre-synaptic dopaminergic function (Dhawan et al., 1996) . However, [ 18 F]dopa is mainly peripherally metabolized in the presence of a peripheral AADC inhibitor (carbidopa), to 3-O-methyl-[ 18 F]dopa by COMT (Boyes et al., 1986) , which then crosses the bloodbrain barrier and contributes to non-specific and striatal [ 18 F] activity. This, along with the formation of other brain dopamine metabolites, makes direct kinetic modelling of k 3 very complex (Gjedde et al., 1991; Kuwabara et al., 1995) and to date has not provided additional biological or clinical information on Parkinson's disease over simpler methods of deriving an [ 18 F]dopa K i o reflecting AADC activity (Dhawan et al., 1996; Ishikawa et al., 1996b; Cumming et al., 1997; Ichise and Ballinger, 1997 ]dopa accumulation and decarboxylation, such as plasma and amino acid concentrations, peripheral and central COMT activities and cerebral blood flow. We have attempted to minimize these effects by fasting all subjects prior to scanning and by using a peripheral COMT inhibitor (Sawle et al., 1994) . We have also used occipital counts for the input function to minimize errors due to attenuation correction, scan detector sensitivity or metabolite correction in 3D. Finally, it should be noted that brain [ 18 F]dopa uptake is a measure of its capacity to decarboxylate exogenous dopa and, as such, measures pre-synaptic dopaminergic function. It does not provide a measure of the endogenous rate of dopamine synthesis.
Another important consideration is the effect of levodopa administration on [ 18 F]dopa uptake in Parkinson's disease. We have found no significant difference in [ 18 F]dopa uptake in early or advanced Parkinson's disease subjects scanned twice within 1 month, on one occasion taking their levodopa medication and on the other occasion off levodopa medication, stopped 12 h prior to their PET scan (R. Ceravalo, unpublished observations). The long-term effects of exposure to levodopa therapy on AADC activity in Parkinson's disease are, however, unknown.
Finally, it has been suggested that to improve region of interest placement, one can co-register each patient ' It is possible that the relative differences in contrast and intensity between [ 18 F]dopa 'add images' and the rCBF template might affect spatial normalization. The normalization process is partly dependent on these factors, but the degree to which it might be affected will also depend on the particular constraints of the normalization programme. In practice, however, the [ 18 F]dopa 'add images' closely resemble the rCBF template (Fig. 2) because the cortex and striatum have relatively high blood flow and the 'add image' incorporates the earlier time frames which are highly blood flow dependent. Furthermore, if the spatial normalization was imprecise this would represent a substantial source of error variance and we would not have obtained high Z scores for [ 18 F]dopa K i o changes in Parkinson's disease. Accurate spatial normalization is further supported by the SPM maps being accurately rendered on to the putamen and caudate regions of the standard normalized MRI, with the maximal scores identified in Talairach space corresponding to putamen and caudate structures (see Fig. 3 ).
In future, however, there is a strong case for developing an [ 18 F]dopa template, rather than using an rCBF template for direct spatial normalization. SPM has now been successfully applied to a number of other PET radioligands (Weeks et al., 1995; Richardson et al., 1996; Piccini et al., 1997) .
We arbitrarily applied minimal Gaussian smoothing (8 mm) in order to increase the signal to noise ratio and therefore the sensitivity. This step did not alter our results and could have been omitted. In general, irrespective of the size of the structure giving a signal, smoothing will increase signal to noise and therefore sensitivity, but will degrade resolution (Friston et al., 1995) .
Finally, addressing the issue of the normal distribution of voxel [ 18 F]dopa K i o values. This assumption is supported by no outliers being observed at the maximal Z score plots in the three Parkinson's disease studies and can be inferred from a normal distribution of region of interest [ 18 F]dopa K i o values in normal and Parkinson's disease populations, both from this and previous PET studies. The unpaired t test is generally considered to be a robust statistical test, capable of handling suboptimal normally distributed data. At Z scores greater than 4.0, the permutation test is thought to be unnecessary (Holmes et al., 1996) .
Extrastriatal changes in early Parkinson's disease
An unexpected finding revealed by SPM was increased [ 18 F]dopa uptake in the anterior cingulate and dorsal midbrain regions in early hemi-Parkinson's disease (see Fig. 3A ). In addition to the reasons already discussed, these extrastriatal [ 18 F]dopa K i o changes are unlikely to be artefactual false positives because the anterior cingulate result was confirmed retrospectively, independent of stereotaxic transformation and SPM, by applying conventional region of interest analysis to the corresponding cingulate regions on the original untransformed images.
With region of interest analysis, we observed similiar mean right and left anterior cingulate [ 18 F]dopa K i o increases but only a significant increase in the left anterior cingulate with SPM. (SPM showed a trend in right cingulate Z ϭ 3.8, P Ͻ 0.076.) However, we applied a larger region of interest than the SPM focus which would have reduced the value of the higher left cingulate
o is unclear but suggests increased AADC activity. There are a number of possible explanations for this finding which are now discussed. Our knowledge of brain AADC activity in health and disease is limited because there are no direct in vivo human studies. Furthermore, there are no post-mortem studies in early hemi-Parkinson's disease to determine directly early striatal and extrastriatal dopaminergic changes. Therefore, the exact pathophysiological changes occurring in dopaminergic neurons in the very early stages of Parkinson's disease are unknown.
The rate limiting step of endogenous dopamine formation within pre-synaptic dopaminergic nerve terminals is tyrosine hydroxylase which converts L-tyrosine to L-dopa. Under normal physiological conditions AADC which converts L-dopa to dopamine is not thought to be regulated. However, a number of studies have suggested that AADC can be regulated under pathophysiological conditions. Human postmortem brain studies have suggested that AADC may be upregulated in dopamine neurons that are spared during ageing (Agid et al., 1987; Kish et al., 1995) , and increased AADC activity has been demonstrated in patients with psychosis (Reith et al., 1994) . It is possible, therefore, that AADC may undergo regional regulatory changes in Parkinson's disease.
The anterior cingulate observation (Brodmann area 24/32) corresponds neuroanatomically to the mesocortical region which receives dopaminergic projections from the ventral tegmental area A10 (Lindvall and Bjorklund, 1974; Simon and Le Moal, 1984) . This projection forms part of the mesocorticolimbic dopaminergic system which is involved in motor, cognitive and behavourial functions (Glowinski et al., 1984; Le Moal and Simon, 1991) . Dopaminergic projections to the cerebral cortex, however, also arise from dopamine neurons in the substantia nigra (Bjorklund and Lindvall, 1984) . The mesocortical system, which includes the pre-frontal region, is distinct from other ascending dopaminergic projections, i.e. nigrostriatal and mesolimbic, and has unique intrinsic properties. For example, they completely lack or have greatly reduced numbers of autoreceptors on their cell bodies, dendrites and nerve terminals. They also have a higher neuronal firing rate, different activity pattern, higher dopamine turnover and a diminshed response to dopamine agonists/antagonists (Bannon and Roth, 1983) .
Another interesting feature of the mesocortical system, which could possibly explain our PET finding, is the inverse relationship demonstrated between the mesocortical and nigrostriatal dopaminergic systems (Pycock et al., 1980) . This was first demonstrated in animal studies where dopaminergic neurons projecting to the mesocortex were specifically lesioned in rats. This led to an increase in dopamine levels, its metabolites and D 2 receptor binding and sensitivity in the striatum. Similiar findings have now been demonstrated in non-human primates (Roberts et al., 1994) . It has therefore been proposed that the mesocortical dopaminergic system has an inhibitory regulatory effect on nigrostriatal dopaminergic systems. Conversely, nigrostriatal lesions could produce an increase in dopamine turnover associated with increased AADC activity in the mesocortex. Surprisingly, there are no studies investigating the reverse relationship.
A further unique feature of the mesocortical dopaminergic neurons is their preferential sensitivity to physical and psychological stress (Roth and Elsworth, 1995) . Therefore our finding could instead represent a stress related response in early Parkinson's disease.
On a general dopaminergic perspective, it has been proposed that there are compensatory or adaptive processes in Parkinson's disease to counterbalance the initial nigral dopaminergic cell loss and that symptoms appear when dopamine depletion reaches a critical threshold and these adaptive processes fail (Zigmond et al., 1990) . One such possible compensatory mechanism could involve increased synthesis and release of dopamine from residual midbrain dopaminergic neurons. Animal studies have shown that partial or unilateral midbrain dopaminergic lesions result in increased dopamine content and turnover in the remaining striatal dopaminergic terminals (Agid et al., 1973; Andersson et al., 1980; Melamed et al., 1982) perhaps related to the sprouting of residual dopaminergic nerve terminals (Blanchard et al., 1996) .
In o , whereas region of interest sampled whole midbrain activity being unable to distinguish clearly between ventral and dorsal midbrain regions on an integrated 'add image'. Although the focus occured at the level of the superior colliculus, it extended forward and may represent the rostral component of the raphe nuclei.
We now know that a single AADC enyzme catalyses the decarboxylation of both L-dopa in catecholaminergic neurons and 5-hyroxytryptophan in serotonergic neurons (Tison et al., 1991) (Figs 1 and  3) . Therefore, our dorsal midbrain finding may represent increased AADC activity in serotonergic neurons in this region.
In a previous PET study of early Parkinson's disease with [ 11 C]WIN 35,428, a cocaine analogue which specifically labels the dopamine transporter, an 84% reduction in midbrain binding was reported (Frost et al., 1993) . We did not observe a reduction in midbrain [ 18 F]dopa uptake in our early hemiParkinson's disease cases. This may reflect either a milder degree of involvement at this stage (their five patients had more advanced and bilateral Parkinson's disease), and/or relative preservation of dopa decarboxylase activity compared with dopamine re-uptake site binding. Alternatively, it has been suggested that dopamine re-uptake sites may be downregulated (Bannon et al., 1992) .
Extrastriatal changes in advanced Parkinson's disease
No significant changes in anterior cingulate [ 18 F]dopa K i o were observed with SPM or conventional region of interest analysis. This result is perhaps surprising given that postmortem data have shown a reduction in frontal dopamine and its metabolites in Parkinson's disease (Scatton et al., 1982) . One possible explanation could be that our advanced Parkinson's disease group did not have significant cognitive impairment. Alternatively, AADC activity may be maintained in mesocortical areas in advanced Parkinson's disease despite a fall in tyrosine hydroxylase activity and dopamine levels.
In the midbrain region significant decreases in [ 18 F]dopa K i o were demonstrated by region of interest analysis and were shown by SPM to involve both ventral and dorsal regions, in particular, the substantia nigra, ventral tegmentum and the median raphe nuclei.
In Fig. 3C) . Surprisingly, these reductions were much more significant than the further striatal losses and suggest marked monoaminergic rather than simply dopaminergic neuronal degeneration in Parkinson's disease. Their exact role in the clinical development and late complications of Parkinson's disease, e.g. motor fluctuations and freezing, and problems of long-term levodopa therapy, e.g. dyskinaesia, is unknown. (Morrish et al., 1995) . In this study, we used a higher resolution 3D PET scanner with greater sensitivity and improved image quality. This resulted in an~40% increase in normal striatal (Rakshi et al., 1996) . Therefore, the conclusion, based on the results of the earlier 2D study, that the ipsilateral putamen in early hemi-Parkinson's disease is not significantly affected, is no longer supported. With further advances in PET technology, we may demonstrate even greater differences.
Striatal changes in Parkinson's disease
In Parkinson's disease, involvement but relative sparing of caudate dopaminergic function is well recognized; however, it is still unclear when and how it develops. With SPM, we detected a significant region of reduced [ 18 F]dopa uptake in the dorsal body of the right caudate in early left hemiParkinson's disease. This suggests preferential targeting of the body as well as head of caudate in early Parkinson's disease. In support of our finding, a post-mortem study has demonstrated severe dopamine depletion in dorsorostral caudate regions comparable with dorsocaudal putamen losses in established Parkinson's disease (Kish et al., 1988) .
In 
